JP4891065B2 - Slurp−1組成物及びその使用方法 - Google Patents
Slurp−1組成物及びその使用方法 Download PDFInfo
- Publication number
- JP4891065B2 JP4891065B2 JP2006506625A JP2006506625A JP4891065B2 JP 4891065 B2 JP4891065 B2 JP 4891065B2 JP 2006506625 A JP2006506625 A JP 2006506625A JP 2006506625 A JP2006506625 A JP 2006506625A JP 4891065 B2 JP4891065 B2 JP 4891065B2
- Authority
- JP
- Japan
- Prior art keywords
- slurp
- acetylcholine receptor
- subject
- protein
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/944—Acetylcholine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4719—G-proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
Description
本発明は、有効量のSLURP−1又は関連タンパク質を神経障害に罹患している対象者に投与することにより対象者の神経障害を処置するための方法を提供する。
本発明は、SLURP−1がアセチルコリン受容体活性を調節する能力に一部基づいている。SLURP−1は、ARS B遺伝子をコードする9kDaのタンパク質である。SLURP−1のアミノ酸配列は103のアミノ酸残基を有する:
MASRWAVQLLLVAAWSMGCGEALKCYTCKEPMTSASCRTITRCKPEDTACMTTLVTVEAEYPFNQSPVVTRSCSSSCVATDPDSIGAAHLIFCCFRDLCNSEL(配列番号2)。
本発明は、有効量のSLURP−1又はSLURP−1可憐タンパク質を神経障害に罹患している対象者に投与することにより当該対象者の神経障害を処置する方法を提供する。
本発明は、有効量のSLURP−1又はSLURP−1関連タンパク質を皮膚病に罹患している対象者に投与することで、皮膚で発現しているアセチルコリン受容体の機能障害により生じた皮膚病を処置するための方法を提供する。
本発明はまた、有効量のSLURP−1、SLURP−1ミメティック、又はそれらの組み合わせ及び担体を含む組成物であって、アルファ7ニコチン性アセチルコリン受容体又は関連タンパク質の機能を調節する組成物も提供する。1つの好ましい態様において、当該組成物はキットの一部として提供される。
本発明はまた、アセチルコリン受容体と有効量のSLURP−1又はSLURP−1関連タンパク質とを接触させることでアセチルコリン受容体の活性を調節する方法であって、前記有効量が約1pM〜約10μMである、方法を提供する。好ましい態様において、アセチルコリン受容体の調節はアセチルコリン受容体の適切な機能を回復させる。
本発明は更に、a)第一アセチルコリン受容体に候補化合物を曝露し、そして当該曝露後の第一アセチルコリン受容体の活性を測定し、b)第二アセチルコリン受容体に有効量のSLURP−1又は関連化合物を曝露し、そして当該曝露後の第二アセチルコリン受容体の活性を測定し、そしてc)最初の曝露後の第一アセチルコリン受容体の活性と、SLURP−1又は関連化合物の曝露後の第二アセチルコリン受容体の活性とを比較すること、により、アセチルコリン受容体活性の調節物質をスクリーニングする方法を提供する。第一アセチルコリン受容体の活性が曝露後の第二アセチルコリン受容体の活性と同程度である場合、前記候補化合物はアセチルコリン受容体活性の調節物質である。
本発明により、SLURP−1に対して高い特異的結合親和性を有する抗体も提供される。当該抗体は、例えばモノクローナル抗体、ポリクローナル抗体又はヒト化抗体であってもよい。例えば、高い特異的結合親和性は、5.0x10-5M未満の解離定数で表されることがある。好ましくは、高い特異的結合親和性は、5.0x10-7M未満の解離定数で表される。更に好ましくは、高い特異的結合親和性は、5.0x10-9M未満の解離定数で表される。
センス5'-AAGCTTGGAGCAATGGCCTCTCGCTGG(配列番号3)及びアンチセンス5'-TCTAGAGAGTTCCGAGTTGCAGAGGTC(配列番号4)。
センス5'-GAGATATCGGAGCAATGGCC-TCTCG (配列番号5)及びアンチセンス5'-AGAGATCTTCACAGATCCTCTT-CTGAGATGAGTTT(配列番号6)。
本発明はそれらの詳細な説明と併せて説明されているが、前述の記載は、特許請求の範囲により規定される本発明の範囲を例示することを意図しており、それらを限定することを意図していない。他の観点、利点及び改変は本発明の特許請求の範囲内である。
Claims (8)
- 統合失調症の治療を必要とする対象者の統合失調症を処置するための、SLURP−1を含んで成る医薬組成物。
- 統合失調症の予防又はその開始の遅延を必要とする対象者の統合失調症を予防又はその開始を遅延するための、SLURP−1を含んで成る医薬組成物。
- SLURP−1が1.0pM〜10μMの濃度である、請求項1又は2に記載の医薬組成物。
- SLURP−1が経口投与、静脈内投与、腹腔内投与、鼻内投与、及び筋肉内投与から成る群から選択される方法で対象者に投与される、請求項1又は2に記載の医薬組成物。
- 対象者内でSLURP−1タンパク質を発現することができる発現ベクターを更に含んで成る、請求項1又は2に記載の医薬組成物。
- SLURP−1が成熟型であり、SLURP−1の成熟型が配列番号2のアミノ酸23〜103を含んで成る、請求項1又は2に記載の医薬組成物。
- 対象者が哺乳類である、請求項1又は2に記載の医薬組成物。
- 哺乳類がヒトである、請求項7に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46341803P | 2003-04-16 | 2003-04-16 | |
US60/463,418 | 2003-04-16 | ||
PCT/IB2004/001716 WO2004091646A2 (en) | 2003-04-16 | 2004-04-16 | Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006523678A JP2006523678A (ja) | 2006-10-19 |
JP4891065B2 true JP4891065B2 (ja) | 2012-03-07 |
Family
ID=33300074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006506625A Expired - Fee Related JP4891065B2 (ja) | 2003-04-16 | 2004-04-16 | Slurp−1組成物及びその使用方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7135454B2 (ja) |
EP (1) | EP1613341B1 (ja) |
JP (1) | JP4891065B2 (ja) |
AT (1) | ATE494903T1 (ja) |
AU (1) | AU2004229237B2 (ja) |
CA (1) | CA2520029C (ja) |
DE (1) | DE602004031003D1 (ja) |
ES (1) | ES2359408T3 (ja) |
IL (1) | IL171384A (ja) |
NO (1) | NO337494B1 (ja) |
WO (1) | WO2004091646A2 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006020996A2 (en) * | 2004-08-11 | 2006-02-23 | Cedars-Sinai Medical Center | Treatment of parkinson's disease and related disorders |
US7858590B2 (en) * | 2005-08-11 | 2010-12-28 | Cedars-Sinai Medical Center | Treatment of parkinson's disease and related disorders |
US20080221013A1 (en) * | 2006-09-02 | 2008-09-11 | Julie Miwa | Neurobiological compositions |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
RU2453602C2 (ru) * | 2010-08-19 | 2012-06-20 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pЕТ22b(+)/SLURP-1, КОДИРУЮЩАЯ БЕЛОК SLURP-1, И ШТАММ БАКТЕРИЙ Escherichia coli BL21(DE3)/pET22b(+)/SLURP-1-ПРОДУЦЕНТ БЕЛКА SLURP-1 ЧЕЛОВЕКА |
CN106074548A (zh) | 2010-09-23 | 2016-11-09 | 艾伯维巴哈马有限公司 | 氮杂金刚烷衍生物的一水合物 |
EP2714096B1 (en) | 2011-06-03 | 2018-02-28 | Ophidion Inc. | Compositions and methods for transport across the blood brain barrier |
US9132193B2 (en) | 2012-11-05 | 2015-09-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of Slurp1 as an imunomodulatory molecule in the ocular surface |
EP2740485B1 (en) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protein slurp-1 for use in the treatment of ocular diseases |
CN114601915B (zh) * | 2022-03-25 | 2023-04-07 | 四川大学华西医院 | Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5298604A (en) * | 1992-07-27 | 1994-03-29 | Sloane Nathan H | Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes |
IT1257184B (it) * | 1992-12-22 | 1996-01-10 | Applied Research Systems | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale |
AU727618B2 (en) | 1996-04-24 | 2000-12-14 | Laboratoires Serono Sa | Component B as cicatrizant |
AU8536698A (en) | 1997-06-09 | 1998-12-30 | Wolf-Georg Forssmann | Lus-1 human protein, its production and use |
WO2000002579A2 (en) | 1998-07-09 | 2000-01-20 | Applied Research Systems Ars Holding N.V. | Component b as angiogenic agent in combination with human growth factors |
-
2004
- 2004-04-16 AT AT04727963T patent/ATE494903T1/de not_active IP Right Cessation
- 2004-04-16 JP JP2006506625A patent/JP4891065B2/ja not_active Expired - Fee Related
- 2004-04-16 EP EP04727963A patent/EP1613341B1/en not_active Expired - Lifetime
- 2004-04-16 DE DE602004031003T patent/DE602004031003D1/de not_active Expired - Lifetime
- 2004-04-16 AU AU2004229237A patent/AU2004229237B2/en not_active Ceased
- 2004-04-16 WO PCT/IB2004/001716 patent/WO2004091646A2/en active Application Filing
- 2004-04-16 CA CA2520029A patent/CA2520029C/en not_active Expired - Fee Related
- 2004-04-16 ES ES04727963T patent/ES2359408T3/es not_active Expired - Lifetime
- 2004-04-16 US US10/826,788 patent/US7135454B2/en not_active Expired - Fee Related
-
2005
- 2005-10-11 IL IL171384A patent/IL171384A/en not_active IP Right Cessation
- 2005-11-10 NO NO20055309A patent/NO337494B1/no not_active IP Right Cessation
-
2006
- 2006-09-06 US US11/516,874 patent/US7691808B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2004091646A3 (en) | 2004-12-16 |
AU2004229237B2 (en) | 2009-06-04 |
AU2004229237A1 (en) | 2004-10-28 |
NO337494B1 (no) | 2016-04-25 |
US20050004025A1 (en) | 2005-01-06 |
ES2359408T3 (es) | 2011-05-23 |
JP2006523678A (ja) | 2006-10-19 |
IL171384A (en) | 2010-12-30 |
WO2004091646A2 (en) | 2004-10-28 |
NO20055309D0 (no) | 2005-11-10 |
CA2520029A1 (en) | 2004-10-28 |
US7135454B2 (en) | 2006-11-14 |
ATE494903T1 (de) | 2011-01-15 |
CA2520029C (en) | 2014-07-15 |
NO20055309L (no) | 2006-01-16 |
EP1613341A2 (en) | 2006-01-11 |
EP1613341B1 (en) | 2011-01-12 |
DE602004031003D1 (de) | 2011-02-24 |
US20070219130A1 (en) | 2007-09-20 |
US7691808B2 (en) | 2010-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7691808B2 (en) | Use of Slurp-1 for treating diseases related to acetylcholine receptor dysfunction | |
Stout et al. | The synaptic vesicle glycoprotein 2: structure, function, and disease relevance | |
US6696303B2 (en) | Identifying substances using cells that express p75NTR | |
ES2341842T3 (es) | Bloqueo del crecimiento axonal mediado por el receptor de nogo. | |
US8703125B2 (en) | Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders | |
US6211149B1 (en) | Inhibitors of formation of protease resistant prion protein | |
JP2002513037A (ja) | Fizzタンパク質 | |
PT1887014E (pt) | Homëlogos de toll humana | |
JP6565121B2 (ja) | 代謝障害を治療する方法 | |
Cappelli et al. | Glycine-induced NMDA receptor internalization provides neuroprotection and preserves vasculature following ischemic stroke | |
CN109593123B (zh) | 一种衍生自rps23rg1的多肽及其应用 | |
US20040191291A1 (en) | Composition and method for nerve regeneration | |
Thompson et al. | Suppression of TNF receptor-1 signaling in an in vitro model of epileptic tolerance | |
JP2010506930A (ja) | Tlr14の活性を変調するための組成物および方法 | |
KR19990007893A (ko) | 중추신경계(cns) 축삭 성장 모듈레이터, 이를 구현 및 사용하는 조성물, 세포 및 방법 | |
US5731410A (en) | Peptide for blocking autoantibody-evoked activation of glutamate receptor type 3 (GLUR3) | |
DE60105609T2 (de) | Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers | |
US7550144B2 (en) | Prion inhibition | |
US20130065825A1 (en) | Compositions and Methods for Delaying Senescence or Cell Death in Neurons | |
US20050288212A1 (en) | Components of the presenilin-complex | |
US20050196757A1 (en) | Identification of a receptor controlling migration and metastasis of skin cancer cells | |
US20040076965A1 (en) | MIA-2 protein | |
O'Malley | The role of sodium channel α and β subunits in myelinating glia and demyelinating disorders | |
Gahring et al. | Neurodegenerative disease and the neuroimmunobiology of glutamate receptors | |
Dai | Regulation of transglutaminase by 5-HT2A receptor signaling and calmodulin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070405 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080625 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100929 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111012 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111028 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111115 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111215 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |